UPDATE: ISI Group Upgrades Vertex Pharmaceuticals
According to a research report published this morning, ISI Group has upgraded Vertex Pharmaceuticals (NASDAQ: VRTX) to Buy.
In the report, ISI Group commented, "Some Street observers we've spoken with are bothered by the lack of a sweat chloride response in this trial. We STRONGLY disagree as sweat chloride is just a surrogate marker. CF patients don't care about their sweat. They care about their lungs. The impact on lungs in this trial appears dramatic to us. We would buy the stock on confusion around this point."
Vertex Pharmaceuticals closed yesterday at $37.41.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.